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SUMMARY
Objective：Transcatheter arterial embolization（TAE）, including uterine artery embolization（UAE）, is 
effective for the management of obstetric and gynecologic hemorrhage. Some adverse effects have been 
reported with TAE, such as amenorrhea, endometrial trauma, and subsequent infertility. Herein we report 
the efficacy and complications of emergent TAE for the management of severe intractable uterine bleeding 
at our institute.
Methods：From 2010 to 2019, thirty-eight patients underwent emergent TAE for intractable uterine 
bleeding. We evaluated the efficacy and complications of TAE, including a change in menstruation, fertility, 
and pregnancy outcomes in perinatal patients（group A；n＝23）, and in patients with gynecologic hemor-
rhage（group B；n＝15）.
Results：In group A, 7 cases of retained placenta, 4 cases of postpartum hemorrhage, 2 cases of placenta 
accrete, 2 cases of uterine artery pseudoaneurysm, 2 cases of cervical pregnancy, 1 case of cesarean scar 
pregnancy, and 5 cases of unexplained hemorrhage were included. The median age of the group A was 37. 
In group B, 4 cases of uterine artery pseudoaneurysm, 2 cases of uterine arteriovenous malformation, 3 
cases of uterine fibroids, 1case of adenomyosis, and 5 cases of unexplained hemorrhage were included. The 
median age of the group B was 39. The first attempt at TAE successfully controlled hemorrhage in 33 of 
38 patients（86.8％）without major complications, and the remaining 5 patients required an additional 
attempt at TAE to control hemorrhage. One patient（2.6％）had transient buttock pain and foot ischemia. 
Among the 33 patients who had adequate follow-up care, all patients resumed regular menstruation. The 
median time to resume regular menstruation after TAE was 3 months（range, 1-13 months）in group A（n
＝20）and 1 month（range, 1-6 months）in group B（n＝13）. Four of patients had 6 pregnancies in total：3 
full-term live births, 2 missed abortions, and 1 artificial abortion. Among the 13 patients who desired preg-
nancy, 3（23％）conceived spontaneously.
Conclusions：This retrospective study showed that emergent TAE may be effective and safe in treating 
intractable uterine bleeding with a high success rate. Ovarian and endometrial function were preserved 
based on the relatively early return of menstruation. Further prospective investigations with large number 
of patients are needed to confirm the preservation of ovarian function, fertility, and pregnancy outcome in 
reproductive-aged women.
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INTRODUCTION
Transcatheter arterial embolization（TAE）, includ-
ing uterine artery embolization（UAE）, is effective for 
the management of obstetric and gynecologic hemor-
rhage. TAE is minimally invasive and fertility-pre-
serving, so it is becoming an alternative to surgical 
procedures. Indeed, the efficacy and safety of TAE for 
the treatment of postpartum hemorrhage（PPH）and 
symptomatic uterine fibroids have been well-estab-
lished 1,2）.
Some adverse effects have been reported with TAE 
in each clinical setting, including amenorrhea, trauma 
to the endometrium, loss of ovarian reserve, and sub-
sequent infertility, although it is still a matter of 
debate 3,4）.
Herein we report the efficacy and complications of 
emergent TAE for the management of severe intrac-
table uterine bleeding at our institute.
MATERIALS AND METHODS
Patient characteristics
From January 2010 to April 2019 , thirty-eight 
patients underwent emergent TAE, including UAE, 
for intractable uterine bleeding at Dokkyo Medical 
University Hospital. The patient population consisted 
of two groups：Group A（n＝23, Table 1）, patients 
with obstetric hemorrhage, and Group B（n＝15 , 
Table 2）, patients with gynecologic hemorrhage 
except for malignancy. The median age for group A 
was 37 years（range, 25-44 years）and the median 
age for group B was 39 years（range, 25-51 years）. 
The etiology of hemorrhage in group A was as fol-
lows：retained placenta, 7；postpartum hemorrhage 
with disseminated intravascular coagulopathy, 4；pla-
centa accreta, 2；uterine artery pseudoaneurysm, 2；
cervical pregnancy, 2；cesarean scar pregnancy, 1；
and unexplained hemorrhage after normal vaginal 
delivery and cesarean section, 1 and 4, respectively
（Table 1）. The etiology of hemorrhage in group B 
was as follows：uterine artery pseudoaneurysm, 4；
uterine arteriovenous malformation, 2；uterine 
fibroids, 3；adenomyosis, 1；and unexplained hemor-
rhage, 5（Table 2）. These patients were diagnosed by 
ultrasonography with color Doppler, MRI, and/or CT, 
and initially treated using standard obstetric and 
gynecologic procedures with emergent medical care. 
The obstetric maneuvers used to control hemorrhage 
included uterine massage, uterine packing, administra-
tion of uterine contraction agents, and appropriate 
treatment for disseminated intravascular coagulation
（DIC）in patients with postpartum hemorrhage（PPH）
for each clinical indication；however, all of the 
patients enrolled in this study were refractory to 
these conservative treatments. In patients with gyne-
cologic hemorrhage, special gynecologic procedures 
except for emergency care were not performed before 
TAE because all of the patients enrolled in the study 
desired less invasive surgery than a hysterectomy 
and the subsequent loss of fertility. TAE, including 
UAE, was performed after consultation with interven-
tional radiologists when obstetrician-gynecologists 
determined that hemostasis was difficult to achieve 
using standard obstetric and gynecologic management
（other than invasive surgical intervention）, after dis-
closing the safety, efficacy, and complication rate of 
TAE, and obtaining informed consent from each 
patient.
This retrospective study was approved by the insti-
tutional review board.
Embolization methods
Digital subtraction angiography（DSA）and subse-
quent TAE were performed with local anesthesia by 
interventional radiologists. First, a 4.0-Fr introducer 
sheath（Radifocus Introducer IIH；Terumo Co., 
Tokyo, Japan）was inserted into the right common 
femoral artery and a 4.2-Fr pig-tailed catheter（Hana-
ko Excellent EN Catheter ［Hi-MAX］；Hanako Medi-
cal Co., Saitama, Japan）was used to assess the inter-
nal iliac arteries and its branches and/or other 
potential bleeding sites, such as ovarian, inferior epi-
gastric, internal pudendal, and vaginal arteries. For 
selective catheterization of the uterine artery, a 2.0-
Fr microcatheter（Michibiki PLUS；Hanaco Medical 
Co.）was passed through the parent catheter with a 
0.016-inch micro-guidewire（Sakigake；Hanaco Medi-
cal Co.）. To embolize the internal iliac artery, glue 
was infused through a 4.0-Fr catheter（Hi-MAX）, the 
tip of which was placed in the anterior trunk and 
gradually pulled back in the main trunk with continu-
ous infusion.
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Gelatin sponge particles（［GS］ Gelpart or Seres-
cue；Nippon Kayaku Co., Tokyo, Japan）were com-
monly selected for absorbable and non-permanent 
embolic materials for TAE；for some patients, tris-
acryl gelatin microspheres（［TAGM］ EmbosphereV 
R；Nippon Kayaku, Co.）were also used. Moreover, 
non-absorbable and permanent embolic materials
（N-butyl-2-cyanoacrylate ［NBCA］ Histoacryl；B. 
Braun, Melsungen, Germany）mixed with iodized oil
（Lioiodol；Guerbet, Tokyo, Japan）at a 1：4 ratio（20
％ glue）was used to achieve complete hemostasis 
with or without GS. A 2 .5-mL syringe containing 
2.5 mL of 20％ glue was connected to the microcathe-
ter and the single-column injection technique was 
used.
The embolic arteries and materials were selected 
by interventional radiologists according to the findings 
of DSA and hemorrhage points in each case.
After embolization of the uterine arteries was com-
pleted, aortography was performed to search for other 
bleeding arteries. The effect of TAE was evaluated 
with respect to complete hemostasis, which was 
defined as hemostasis achieved by TAE alone and 
requiring no additional hemostatic interventions.
Follow-up
The patients were generally followed up at 2 weeks, 
1 month, 3 months, 6 months, and thereafter at an 
internal of 3-6 month. Ultrasonography with color 
Doppler was routinely used if it was thought to be 
useful for each case, and pelvic MRI was scheduled 
3-6 months after embolization as needed.
Changes in symptoms, complications associated with 
TAE, time to resumption of menstruation, time to 
pregnancy after TAE, and pregnancy outcomes were 
obtained from the medical records, and were com-
pared between Group A and B to evaluate the efficacy 
and complications of TAE.
RESULTS
In group A, the following arteries were embolized：
uterine arteries, 17；internal iliac arteries, 9；ovarian 
artery, 2；and artery of the round ligament from the 
external iliac artery（there was some overlap）, 1. In 
group B, the following arteries were embolized：uter-
ine arteries, 15；and ovarian artery, 1. These findings 
showed that embolization of multiple arteries, includ-
ing the uterine arteries, was needed to control obstet-
ric hemorrhage compared to gynecologic hemorrhage.
In group A, the following embolic materials were 
used：GS, 13 patients；and NBCA, 14 patients（there 
was some overlap）. In group B, the following embolic 
materials were used：GS, 13 patients；NBCA, 4 
patients；and TAGM, 2 patients. These findings 
showed that NBCA was more frequently used as an 
embolic material for controlling obstetric hemorrhage 
compared to gynecologic hemorrhage. In group A, 
methotrexate was used combined with GS for 2 
patients with cervical pregnancy.
The first emergent TAE attempt successfully con-
trolled intractable hemorrhage in 33 of 38 patients
（86.8％）without major complications. The remaining 
5 patients needed an additional TAE attempt to con-
trol hemorrhage, as follows：cervical pregnancy, 1；
unexplained hemorrhage after cesarean section, 1；
uterine artery pseudoaneurysm, 2；and unexplained 
hemorrhage（suspicious of uterine vessels abnormali-
ty）, 1（Tables 1 & 2）. Hemostasis was confirmed in all 
5 patients who underwent a 2 nd TAE attempt, there-
fore the success rate of controlling intractable uterine 
bleeding by TAE alone was 100％（38/38 patients）.
Hysterectomy after the first TAE attempt was sub-
sequently required as radical treatment in 3 patients 
for the following indications：adenomyosis；uterine 
cervical fibroid；and placenta accreta（one each）.
One patient（2.6％）had transient buttock pain and 
foot ischemia, which promptly resolved without treat-
ment.
The median follow-up period after TAE was 26.5 
months（range, 4 - 1 1 4 months）. Among the 3 3 
patients in whom follow-up was adequate, all 33 
resumed normal menstruation. The median time to 
resume regular menstruation after TAE was 3 
months（range, 1-13 months）in group A（n＝20）and 
1 month（range, 1-6 months）in group B（n＝13）. The 
patient in group A who had transient buttock pain 
and foot ischemia, also had hypomenorrhea, which 
gradually resolved. There was no apparent relation-
ship between the length of time for normal menstrua-
tion to resume and the vessels embolized or the 
embolic materials used.
Four patients had 6 pregnancies in total：3 full-
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term live births, 2 missed abortions, and 1 artificial 
abortion. Among 13 patients who desired pregnancy, 
3（23％）conceived spontaneously. Among the 3 full-
term live births, there were no major obstetric com-
plications except for a 1300 mL PPH（unknown etiolo-
gy）in 1 patient.
DISCUSSION
The efficacy and safety of TAE, including UAE, for 
the management of intractable uterine bleeding have 
been reported for obstetric hemorrhage due to PPH, 
abnormal placentation, and cervical ectopic pregnancy, 
and for gynecologic hemorrhage due to uterine 
fibroids, adenomyosis, or uterine vessels abnormali-
ties 1,2）. Obstetric hemorrhage remains a major cause 
of maternal morbidity and mortality and TAE has 
been recommended as the first choice of treatment 
for PPH when uterine balloon tamponade fails to con-
trol hemorrhage. Intractable gynecologic hemorrhage 
can lead to surgical interventions, including hysterec-
tomy, and subsequent loss of fertility in reproductive-
aged women.
Therefore, the role of TAE has recently become the 
subject of debate for these conditions. Although there 
are no fundamental objections regarding the effective-
ness of TAE for the management of intractable uter-
ine hemorrhage, there are several unresolved issues 
involving the effects of TAE on ovarian function, fer-
tility, and pregnancy outcome.
Efficacy
The success rate of TAE for obstetric hemorrhage 
due to intractable PPH has been reported to be 87％
〜100％1）, and 90.7％（95％ confidence interval ［CI］；
85.7％ −94.0％）in a systematic review for this condi-
tion 5）. This success rate for TAE is equivalent or 
superior to other surgical approaches ［84.0％ for bal-
loon tamponade, 91 . 7％ for uterine compression 
sutures, and 84.6％ for iliac artery ligation of uterine 
devascularization］5）. The overall treatment failure 
rate for PPH resulting from abnormal placentation, 
such as placenta increta or percreta, which appears to 
be resistant to TAE and the main cause of hysterec-
tomy after failed TAE, has been reported to be as 
high as 23％6）. Moreover, the success rate for TAE is 
lower in patients with DIC, 37.5％ of whom develop 
complications 7）.
For gynecologic hemorrhage, especially symptomat-
ic uterine fibroids, symptoms（menorrhagia, metror-
rhagia, pelvic pain, and bulk symptoms）were signifi-
cantly decreased after TAE 8）. The duration of 
menstruation was shortened, the fibroid volume was 
significantly reduced 8）, and the hospital stay was 
shorter and recovery was faster compared with the 
surgery group 3）. Notably, repeat TAE or hysterecto-
my post-TAE was required for some patients due to 
inadequate symptom control.
Based on a randomized controlled trial（RCT）that 
compared TAE and hysterectomy in the treatment of 
severe symptomatic uterine fibroids, after 10 years of 
follow-up, 69％ of all women underwent technically 
successful TAE and a hysterectomy was avoided. 
Moreover, the health-related quality of life and 
patient satisfaction rates did not differ between both 
groups 9）. In view of the short- and long-term clinical 
and quality-of-life evidence that is available, it was 
concluded that all women who are candidates for hys-
terectomy due to symptomatic uterine fibroids should 
be offered TAE as a treatment option 9）.
In the current study, TAE was also extremely 
effective in controlling intractable hemorrhage. The 
first emergent TAE attempt successfully controlled 
hemorrhage in 33 of 38 patients（86.8％）, and in the 
remaining 5 patients, complete hemostasis was 
achieved with an additional TAE attempt, thus 
achieving a success rate with TAE of 100％（38/38 
patients）. Among the 4 patients with PPH and DIC, 
the initial emergent TAE was effective without any 
complications.
Ovarian artery embolization（OAE）with UAE has 
been reported to control severe PPH10）. In the current 
study, OAE was required to achieve complete hemo-
stasis for 3 patients due to a cervical pregnancy, 
unexplained hemorrhage after a normal vaginal deliv-
ery, and a uterine artery pseudoaneurysm（Tables 1 
& 2）. It is well-known that OAE through uterine-to-
ovarian artery anastomosis is an aggressive emboliza-
tion technique 11）. TAE of the utero-ovarian collateral 
circulation is the most likely mechanism underlying a 
decline in ovarian reserve and premature meno-
pause 11）；however, in the current study 3 patients 
who underwent OAE reported prompt resumption of 
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normal menstruation between 1 and 3 months.
Embolic materials
Several embolic materials have been used in TAE. 
In the current study, GS and NBCA were used in 13 
and 14 patients in group A, respectively, while GS, 
NBCA, and TAGM were used in 13, 4, and 2 patients 
in group B, respectively. This finding showed that 
NBCA was more frequently used as an embolic mate-
rial for controlling obstetric hemorrhage compared to 
gynecologic hemorrhage.
NBCA is indicated for various conditions, including 
vascular diseases（aneurysms and malformations）, 
hemorrhage（trauma and inflammation）, tumors, and 
venous disease（varices）, regardless of the location of 
the target lesion. TAE with a NBCA-Lipiodol mixture 
has been reported to be highly effective in achieving 
hemostasis in patients with PPH accompanied by DIC 
and might be the first-line therapeutic strategy, espe-
cially for patients with desired fertility 12）.
More recently, TAGM has been used for emboliza-
tion instead of GS. The outcomes of TAE with TAGM 
are comparable to TAE with GS, suggesting that both 
embolic agents are acceptable for the treatment of 
uterine fibroids 13）.
The success rate of achieving immediate complete 
hemostasis may be dependent, in part, on the choice 
of embolic materials and embolic vessels. Our study 
showed that embolization of multiple arteries（primari-
ly the uterine arteries）is needed to control obstetric 
hemorrhage compared to gynecologic hemorrhage, 
and NBCA is more frequently used for controlling 
obstetric hemorrhage compared to gynecologic hemor-
rhage.
Safety
TAE is thought to negatively impact endometrial 
blood flow, ovarian blood flow, endocrine function, and 
follicular development. The complication rate of TAE 
is 6％〜9％ and includes amenorrhea, permanent ovar-
ian failure, fertility, transient fevers, groin hematomas, 
contrast reactions, pseudoaneurysms, and iliac artery 
perforation 1,14,15）. Ischemic complications, such as tran-
sient buttock or foot ischemia, small bowel necrosis, 
and uterine, vaginal, cervical, and bladder necrosis, 
are rarely reported 1）. Neurologic complications are 
also rare, such as neuropathies involving the sciatic 
nerve, perineal nerve, and lower limbs 1）.
There were no significant complications related to 
TAE in the current study with the exception of one 
patient who had transient buttock pain and foot isch-
emia.
It has been reported that skillful catheterization, 
proper and gentle injection of embolic materials, and 
choosing the appropriate vessels obviate complica-
tions 16）. Therefore, the incidence of complications fol-
lowing TAE may be extremely low when TAE is per-
formed by a well-prepared team together with 
interventional radiology specialists.
Changes in menstruation
It has been reported that all patients treated for 
PPH resumed normal menstruation 1）. There is a 
report that the most common untoward effect in 
patients with PPH undergoing TAE with GS for 
symptomatic uterine fibroids is transient amenor-
rhea；menorrhagia improved in 90％ of patients 12 
months after treatment, although permanent amenor-
rhea was reported in 2 of 33 patients ［6％］2）.
In the current study, among the patients who had 
adequate follow-up evaluations, normal menstruation 
was restored in all 33 patients. Relatively early 
resumption of menstruation after TAE was observed 
in patients with obstetric（median, 3 months）and 
gynecologic hemorrhage（median, 1 month）；only 1 
patient had transient hypomenorrhea. Based on these 
results, it can be concluded that menstruation is not 
adversely affected by TAE.
Ovarian function
McLucas et al. 17） reported that serum hormone lev-
els, such as follicle-stimulating hormone（FSH）, anti-
Müllerian hormone（AMH）, and estradiol（E2）, are 
not changed by TAE, suggesting that ovarian function 
is not adversely affected, and therefore women of 
reproductive age with uterine fibroids may consider 
TAE as a treatment option. Based on a study with a 
large sample size, it was confirmed that TAE did not 
affect ovarian reserve in women＜40 years of age, as 
evidenced by no significant change in AMH levels 
after embolization 18）.
There is a report, however, that the AMH level 
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recovered in patients treated for uterine fibroids who 
were＜40 years of age, but not in patients ≧40 years 
of age 19）. The subtle difference in ovarian failure rates 
between TAE for PPH and TAE for fibroids may be 
explained by the younger age of patients undergoing 
the former procedure 20）.
Therefore, additional prospective studies with a 
large number of patients are warranted to better elu-
cidate the relationship between patient age and 
changes in ovarian function after TAE for obstetric or 
gynecologic hemorrhage.
Fertility
The 2013 Royal College of Obstetricians and Gyne-
cologists guidelines conclude that there is poor evi-
dence regarding TAE and fertility, and therefore rec-
ommends that women of childbearing age who wish 
to become pregnant in the near future should be 
offered TAE only after an informed discussion 21）.
Preservation of fertility has been reported in 
patients with uterine fibroids 22）or intractable PPH 22）. 
In a systematic review, Mohan et al. 22）reported that 
pregnancy rates following TAE are comparable to 
age-adjusted rates in the general population. McLucus 
et al. 24）also reported in a review that pregnancy rates 
following TAE and myomectomy（48％ and 46％ for 
abdominal and laparoscopic myomectomy, respective-
ly）were comparable and concluded that TAE is a 
valid alternative to myomectomy for women who 
wish to conceive. Moreover, Cheng et al. 23）reported 
that of 23 patients who attempted pregnancy, 19（82.6
％）conceived, giving birth to 12 full-term live infants.
A possible adverse effect of TAE on fertility poten-
tial in patients with uterine fibroids has been report-
ed 8）, especially in the patients＞40 years of age 25）. 
Specifically, Torre et al. 8）reported that TAE might 
have had a negative impact on fertility, which may 
not be related to ovarian function. Therefore, TAE 
should not be performed routinely in young women of 
reproductive age and extensive fibroids. TAE should 
only be considered after appropriate counselling with 
the women who still wish to conceive.
In the current study, among 13 patients who had 
desired fertility, 3（23％）had natural conceptions. The 
pregnancy rate was relatively low compared with pre-
vious reports 23,24）, possibly because the information 
regarding fertility in each patient was insufficient. 
Indeed, the follow-up period for some patients was 
relatively short and the information was only obtained 
from the medical records.
Based on the aforementioned studies, the adverse 
effects of TAE on fertility remain controversial and 
warrant further study.
Pregnancy outcomes
The pregnancy complication rates have been 
reported to be similar in patients with untreated uter-
ine fibroids 22）；however, higher pregnancy loss rates 
following TAE have been reported in patients with 
uterine fibroids compared with patients who have 
undergone a myomectomy 22,26 ,27）. In a systematic 
review Karlsen et al. 26）reported a pregnancy rate of 
50％（13/26）after TAE and 78％（31/40）after myo-
mectomy（no statistical difference）and a pregnancy 
loss rate of 60％（9/15）after TAE and 20％（6/15）
after myomectomy ［p＜0.05］. Karlsen et al. 26）conclud-
ed that the pregnancy rate was lower and the preg-
nancy loss rate was higher after TAE than myomec-
tomy. Karlsen et al. 26）also found very low-quality 
evidence regarding the assessed outcomes and the 
reported proportions are uncertain. Homer et al. 27）
reported that the risk for pregnancy loss appeared to 
be increased after TAE compared with pregnancies 
complicated by fibroids matched for age and fibroid 
location（odds ratio ［OR］ 2.8, p＜0.0001）, and there 
was an increased risk for cesarean section（OR 2.1, p
＜0.0001）and PPH（OR 6.4, p＜0.0001）. In contrast, 
the risks for critical adverse obstetric complications, 
fetal growth restriction（FGR）, preterm delivery, and 
malpresentation were no more likely after TAE when 
compared with women with untreated fibroids.
The increase in miscarriage rate suggests that the 
endometrial cavity incurs irreversible damage as a 
consequence of embolization. TAE-induced endometri-
al ischemia imparts a marked deleterious effect on 
potential implantation sites. A reduction in fibroid vol-
ume after TAE could result in distortion of the endo-
metrial cavity, which is almost certain to escalate the 
risk for pregnancy loss in combination with relative 
endometrial ischemia 27）.
While subsequent pregnancies are clearly possible 
after TAE for PPH, there are reports of recurrent 
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severe PPH at subsequent deliveries ［31.6％ -100
％］20,28）. It has been reported that TAE after the first 
delivery with PPH increased the rate of TAE after 
the second delivery ［OR, 25 . 56；95％ CI, 9 . 86-
66.23］29）. The increased risk for PPH is likely due to 
myometrial compromise as a consequence of emboliza-
tion-induced ischemia, which might contribute to a 
reduced capacity for efficient contractility after deliv-
ery and consequently to uterine atony.
In the current study, 4 patients had 6 pregnancies 
in total, including 3 full-term live births and 2 missed 
abortions. Of the 3 full-term live births, one had a 
PPH, although the reason was not specifically identi-
fied. The pregnancy loss rate in the current study 
was 33％（2/6）, which is consistent with previous 
reports 26 ,27）. The incidence of PPH in subsequent 
deliveries after TAE was also the same as in a previ-
ous report 29）.
There are reports that pregnancy outcome is not 
affected by TAE in PPH patients 23,30）.
The adverse effects on pregnancy outcome are also 
controversial. Therefore, to formally address the 
impact of embolization on pregnancy risk profiles, a 
prospective study that incorporates TAE and non-
treatment arms is needed.
There were some limitations in this study. First, 
this was a retrospective study and the sample size 
was relatively small. Second, many causes of obstetric 
or gynecologic hemorrhage were included in this 
study, and the efficacy and complications of TAE 
were analyzed in all patients. Therefore, it is some-
what difficult to precisely assess the effect of TAE on 
menstruation, fertility, ovarian function, and pregnan-
cy outcome because of the diverse patient back-
grounds.
Nevertheless, the current study demonstrated the 
high success rate of TAE for emergency treatment of 
various causes of intractable hemorrhage without any 
deaths or major complications. One of the reasons for 
these excellent results may be that TAE was per-
formed skillfully together with an interventional radi-
ologists and a well-trained special team using a specif-
ic protocol.
There are many reports, such as meta-analyses, 
RCTs, and case series, regarding the efficacy and 
complications of TAE；however, there were differenc-
es in TAE treatment protocols, patient backgrounds, 
embolic materials used or embolic vessels targeted, 
duration of follow-up, and skills of the interventional 
radiologists in each study. Therefore, it is difficult to 
compare the results of each report regarding efficacy, 
safety, and short- and long-term complications. 
Indeed, based on a review of fertility after TAE, 
Karlsen et al. 26）reported very low-quality evidence 
regarding the assessed outcomes. There is a need for 
well-designed prospective randomized studies to 
improve the evidence base.
There is no doubt that ovarian function, fertility, 
and pregnancy outcomes are for the most part unaf-
fected by TAE based on recent studies. In patients 
with symptomatic uterine fibroids and desired fertility, 
TAE is becoming a valid alternative to myomectomy, 
although not a perfect alternative, but TAE should be 
included as a treatment option for all patients.
CONCLUSION
In conclusion, based on our retrospective study, 
emergent TAE may be effective and safe in treating 
intractable uterine bleeding with a high success rate 
and without major complications. Ovarian or endome-
trial function may be sufficiently preserved based on 
the relatively early recovery of normal menstruation 
after TAE. Nevertheless, there are inconsistent results 
regarding the effects of TAE on ovarian function, fer-
tility, and pregnancy outcomes based on previous 
studies. Further prospective studies with a large num-
ber of patients are needed to confirm the preservation 
of ovarian function, fertility, and pregnancy outcomes 
in reproductive-aged women.
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